DB14211ApprovedProtein Based Therapies
Fanolesomab is an anti-SSEA-1 monoclonal antibody used for imaging of the appendix and to diagnose appendicitis.
- First approval
- United States, 2007
- Also known as
- Monoclonal antibody anti-SSEA-1
- Code names
- RB5-IGM
Resolves to
Compound
Clinical / RWD
What you can answer from here — as of March 06, 2025
Which companies are running trials of Fanolesomab, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account